A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys)180 microg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B.
Phase of Trial: Phase II
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PADD-ON
- 14 Apr 2018 Primary endpoint (Difference in percentage of patients between treatment and comparator arm reaching a 1log10 decline of quantitative HBsAg after 48 weeks) has been met, according to the results presented at The International Liver Congress 2018
- 14 Apr 2018 Results presented at The International Liver Congress 2018
- 01 Mar 2018 Status changed from active, no longer recruiting to completed.